Key issues in the treatment of advanced breast cancer. Expectations and outcomes

PharmacoEconomics

Volumn 9, Issue SUPPL. 2, 1996, Pages 1-7

  Rubens, R D ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GESTAGEN; GONADORELIN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PACLITAXEL; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; CONFERENCE PAPER; FEMALE; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0029909308     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199600092-00003     Document Type: Conference Paper

References (15)

1. Cancer Research Campaign. Incidence - UK Fact Sheet II 1992
2. Coleman RE, Rubens RD. The clinical course of bone metastases in breast cancer. Br J Cancer 1987; 55: 61-6
3. Englesman E, Klijn JCM, Rubens RD, et al. 'Classical' CMF versus a three-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. Eur J Cancer 1991; 27: 966-70
4. Butta A, MacLennan K, Flanders KC, et al. Induction of transforming growth factor beta-1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261-4
5. Santen RJ, Santner SJ, Davis B, et al. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978; 47: 1257-65
6. Spielmann M. Taxol (paclitaxel) in patients with metastatic breast carcinoma who have failed prior chemotherapy: interim results of a multinational study. Oncology 1994; 51: 25-8
7. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314-22
8. ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 1994; 5: 527-32
9. Rubens RD. Single agent chemotherapy. In: Powles TJ, Smith IE, editors. Medical management of breast cancer. London: Martin Dunitz Ltd, 1991: 133-7
10. Steiner R, Stewart JF, Cantwell BMJ, et al. Adriamycin alone or in combination with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol 1983; 19: 1553-7
11. Fischer J, Rose CJ, Rubens RD. Duration of complete response to chemotherapy in advanced breast cancer. Eur J Cancer 1982; 18: 747-54
12. Gregory WM, Smith P, Richards MA, et al. Chemotherapy for advanced breast cancer: outcome and prognostic factors. Br J Cancer 1993; 68: 988-95
13. Selby PJ, Robertson B. Measurement of quality of life in patients with cancer. Cancer Surv 1987; 6: 521-43
14. Rubens RD, Towlson KE, Ramirez AJ, et al. Appropriate chemotherapy for palliating advanced cancer. BMJ 1992; 304: 35-40
15. Richards MA, Braysher S, Gregory WM, et al. Advanced breast cancer: use of resources and cost implications. Br J Cancer 1993; 67: 856-60